Potential impact of oral contraceptive choice on myocardial infarction mortality and deep vein thrombosis

Journal of Family Planning and Reproductive Health Care

Volumn 31, Issue 1, 2005, Pages 37-39

  Martin, Karin ^a   Moride, Yola ^b   Metge, Colleen ^c   Moore, Nicholas ^a   Bégaud, Bernard ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; EPIDEMIOLOGICAL DATA; FEMALE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MORTALITY; ORAL CONTRACEPTION; POPULATION RISK; RISK ASSESSMENT; RISK FACTOR;

EID: 12344259490     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/0000000052972988     Document Type: Article

References (33)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
2. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
3. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-1596.
4. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 83-88.
5. Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, Bruppacher R, Thorogood M. Third generation oral contraceptives and risk of rnyocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 88-90.
6. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-88.
7. Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998; 57: 67-70.
8. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998; 57: 291-301.
9. Bloemenkamp KW, Rosendaal FR, Buller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159: 65-70.
10. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-128.
11. Parkin L, Skegg DC, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet 2000; 355: 2133-2134.
12. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190-1195.
13. Suissa S, Biais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-146.
14. Suissa S, Spitzer WO, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000; 15: 817-821.
15. Farley TM, Meirik O, Marmot MG, Chang CL, Poulter NR. Oral contraceptives and risk of venous thromboembolism: impact of duration of use. Contraception 1998; 57: 61-65.
16. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493-1499.
17. Todd J, Lawrenson R, Farmer RD, Williams TJ, Leydon GM. Venous thromboembolic disease and combined oral contraceptives: a reanalysis of the MediPlus database. Hum Reprod 1999; 14: 1500-1505.
18. Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae KD, Tyrer F, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000; 49: 580-590.
19. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 131-134.
20. European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, Public Assessment Report (EMEA/CPMP/2201/01/en/ Final). Combined oral contraceptives and venous thromboembolism. 2001. http://www.emea.eu.int/pdfs/human/regaffairs/0220101en.pdf) [Accessed 3 February 2004].
21. Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001; 64: 125-133.
22. Lidegaard O, Edstöm B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187-196.
23. Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999; 318: 1579-1583.
24. World Health Organization. Acute myocardial infarction combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997; 349: 1202-1209.
25. Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and occurrence of acute myocardial infarction in young women: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997; 56: 129-140.
26. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345: 1787-1793.
27. Lidegaard O, Eström B. Oral contraceptives and acute myocardial infarction: a case-control study (Abstract). Eur J Contracept Reprod Health Care 1996; 1: 74.
28. PubMed. National Library of Medicine. NCBI Databases. http://www.ncbi.nlm.nih.gov/pubrned [Accessed 23 August 2004].
29. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
30. Bajos N, Leridon H, Goulard H, Oustry P, Job-Spira N and the COCON Group. Contraception: from accessibility to efficiency. Hum Reprod 2003; 18: 994-999.
31. Gender- and age-specific mortality rates for the French general population published yearly by the Institut National de la Santé et de la Recherche Médicale (INSERM). http://sc8.vesinet.inserm.fr:1080 [Accessed 23 August 2004].
32. Szarewski A, Mansour D. The 'pill scare': the responses of authorities, doctors and patients using oral contraceptives. Hum Reprod Update 1999; 5: 627-632.
33. Spitzer WO, Faith JM, MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod 2002; 17: 2307-2314.x